Anti–PD-L1 Immunotherapies in Cancer Patients With Pre-Existing Systemic Sclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
Eur. J. Cancer 2021 Nov 19;[EPub Ahead of Print], M Panhaleux, O Espitia, B Terrier, G Manson, A Maria, S Humbert, B Godbert, J Perrin, A Achille, J Arrondeau, M Kostine, V Fallet, G Pugnet, B Chaigne, S Champiat, A Laparra, FX Danlos, D Launay, N Penel, O Lambotte, JM Michot, A ForestierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.